Metabolic Disorders And Clinical Progress Of Benign Prostatic Hyperplasia Correlation Analysis

Objective: By age is over 50 years old with severe lower urinary tract symptoms in older men as the research object, through the analysis of the correlation between the clinical progression of metabolic disturbance factors and benign prostatic hyperplasia(BPH) to explicitly promotes the development of BPH associated metabolic risk factors, to clinical work actively monitoring and control of risk factors and provide a theoretical basis and to reduce the incidence of BPH, the prevention of disease progression and improve the quality of life of elderly men.Methods: The information of patients with moderate and severe lower urinary tract symptoms were collected from the Department of Urology of the first hospital of Shanxi Medical University between January 2013 and June 2015, and the data were analyzed and studied. The study from the survey data in the selected the following indicators:(1)metabolic factors related to the examination data: height, weight, BMI, blood lipid(TC, TG, HDL-C, LDL-C), fast blood glucose(FBG), uric acid(UA), alanine amino transfer enzyme(ALT), lipoprotein(a)(LP(a)), fibrinogen(FIB), blood pressure;(2) BPH related examination data: lower urinary tract symptoms(LUTS) appear time, PSA and prostate volume(PV), prostate with an average annual growth rate(PG), postvoid residual urine volume(PVR),maximal flow rate(Qmax), International Prostate Symptom Score and Quality of Life score results. According to the number of metabolic disorderfactors they met and the volume of prostate group, combined with the risk factors of MTOPS in BPH clinical progression by correlation analysis.Results: 1. According to the number of factors of metabolic disorders, the subjects were divided into four groups after the show, with the increase in the number of factors of metabolic disorders, prostate volume and annual growth rate showed an increasing trend(F=219.672, p < 0.001); at the same time, between the different groups, PSA, PVR, Qmax and IPSS score differences were statistically significant(p < 0.05). 2. Reference MTOPS five BPH clinical progression factors, 276 cases of patients with a total of 248(89.86%) had at least one risk factors for progression, all of the risk factors in each group were statistically significant, at the same time, with three risk factors of prostate volume > 31cm3, Qmax < 10.6ml/s, PVR> 39 ml patients the proportion of in with the increase in the number of factors of metabolic disorders, showing obvious upward trend(p < 0.001). 3. According to 276 patients with median prostate volume:PVm=47.01cm3, the subjects were divided into four groups,between the two groups comparison showed that body weight(p = 0.019) and BMI(p = 0.002), TG(p = 0.004), FBG(p = 0.003), the number of metabolic disorder factors(p < 0.001) have significant difference and the index mean in the larger prostate volume group were significantly larger. 4.PV>31cm3 and MS(OR=0.269, CI:0.094-0.768), hypertension(OR=1.956, CI:1.061-3.608), BMI(OR=3.138,CI:1.340-7.350),TG(OR=2.950 CI:1.323-6.577) has a significant correlation. 5. Qmax<10.6ml/s and MS(OR=0.385,CI:0.158-0.939),TG(OR=3.468, CI: 1.799-6.687), FBG(OR=1.228, CI: 1.034-1.459) has a significant correlation. 6. PSA> 1.6ng / ml and BMI(OR=2.048,CI:1.009-4.156),TG(OR=2.622, CI:1.298-5.297) has a significant correlation.Conclusion: 1. With the increase of the number of metabolic disorder factors, prostate volume and annual growth rate showed an increasing trend, suggesting that the greater the degree of aggregation of metabolic disorders, the faster progress of BPH. 2.PV>31cm3、Qmax<10.6ml/s、PVR≥39ml,these three risk factors with the increase in the number of factors of metabolic disorders, showed a clear upward trend, suggesting that these three risk factors on the progression of BPH decisive role. 3. The correlation between the PV>31cm3 and MS, BMI, hypertension, hyperlipidemia, combining with the correlation between Qmax<10.6ml/s and MS, hyperlipidemia, high blood glucose, suggesting that the metabolic disturbance factors of the enlargement playing an important role of the prostate and bladder function decline in the disease process, but the exact mechanism still need to further study. 4. Clinical active monitoring and early control of the risk of yin deficiency, so as to reduce the incidence of BPH, prevent disease progression, improve the quality of life of elderly men.